PHAXIAM TX news, videos and press releases
For more news please use our advanced search feature.
PHAXIAM TX - More news...
PHAXIAM TX - More news...
- PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure
- PHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication
- PHAXIAM Therapeutics: Press Release Regarding Suspension of Trading
- PHAXIAM Therapeutics and Technophage Enter Strategic Collaboration On Individualized GMP Phages Therapies (IPT) Against Bacteria Responsible For ~ 70%(1) Of The Most Common Severe Resistant Infections
- PHAXIAM Therapeutics Announces Its Financial Calendar for 2025
- PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe
- PHAXIAM: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – December 31, 2024
- PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study
- PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"
- PHAXIAM Reports Third-Quarter 2024 Financial Information
- PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.
- Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024
- PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study
- PHAXIAM Provides Business and Financial Update For the First Half of 2024
- PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024
- Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2024
- Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024
- PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
- Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024
- PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
- PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
- PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
- Monthly information related to total number of voting rights and shares composing the share capital - November 30, 2023
- Monthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023
- PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus
- Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2023
- Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
- ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
- ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023
- ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
